Wedbush reiterated their buy rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report issued on Monday, AnalystRatings.com reports. Wedbush currently has a $219.00 target price on the biotechnology company’s stock. Wedbush also issued estimates for Ascendis Pharma A/S’s FY2023 earnings at $13.57 EPS.

Several other equities research analysts have also recently issued reports on the stock. BidaskClub raised shares of Ascendis Pharma A/S from a hold rating to a buy rating in a research note on Thursday, January 10th. Leerink Swann raised shares of Ascendis Pharma A/S from a market perform rating to an outperform rating and lifted their target price for the stock from $73.00 to $90.00 in a research note on Thursday, January 24th. Zacks Investment Research cut shares of Ascendis Pharma A/S from a buy rating to a hold rating in a research note on Thursday, January 24th. Canaccord Genuity lifted their target price on shares of Ascendis Pharma A/S from $132.00 to $133.00 and gave the stock a buy rating in a research note on Friday, April 5th. Finally, Cantor Fitzgerald reaffirmed a buy rating and set a $185.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, March 18th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Ascendis Pharma A/S currently has a consensus rating of Buy and a consensus target price of $135.56.

Ascendis Pharma A/S stock opened at $120.60 on Monday. Ascendis Pharma A/S has a 1 year low of $53.21 and a 1 year high of $131.76. The firm has a market capitalization of $5.01 billion, a P/E ratio of -32.25 and a beta of 1.01.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.30. Ascendis Pharma A/S had a negative net margin of 1,275.08% and a negative return on equity of 40.86%. The firm had revenue of $12.00 million for the quarter. Equities analysts expect that Ascendis Pharma A/S will post -3.86 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in ASND. Putnam Investments LLC acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth $11,653,000. Bank of New York Mellon Corp acquired a new stake in Ascendis Pharma A/S during the 4th quarter worth $7,732,000. Loomis Sayles & Co. L P acquired a new position in shares of Ascendis Pharma A/S during the 3rd quarter valued at about $6,240,000. Westpac Banking Corp acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter valued at about $5,461,000. Finally, New York State Common Retirement Fund boosted its position in shares of Ascendis Pharma A/S by 44.4% during the 4th quarter. New York State Common Retirement Fund now owns 233,049 shares of the biotechnology company’s stock valued at $14,601,000 after acquiring an additional 71,656 shares during the last quarter. 95.46% of the stock is currently owned by institutional investors.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Story: Gap Up Stocks

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.